Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blow-Fill-Seal Sterile CDMO Business is focusing on complex clinical to commercial-stage formulation and manufacturing. The Business supports a global, blue-chip customer base with a broad array of products that leverage its BFS sterile manufacturing capabilities and formulation competency in complex chemistries including small molecule, biologics, macromolecules, and potent compounds.

Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) announced today that the Company has received written notification (“Notice”) from the New York Stock Exchange (“NYSE”) that it has officially regained compliance with the NYSE continued listing standards. Following the filing by the Company on December 8, 2023 of its Annual Report on Form 10-K for the year ended June 30, 2023 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023,.

Catalent Regains Compliance with NYSE Continued Listing Standards

Allstate

Arista Networks

Carnival

Chipotle

Centene

Expedia

Intel

NVIDIA

Warner Bros Discovery Inc

Zions Bancorp

Hope you didn't bail out of S&P 500 stocks after three-straight months of losses. November turned into a big moneymaker.

11 Stocks Turn $10,000 Into $230,769 In 11 Months

Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.

Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales

The headline numbers for Catalent (CTLT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Catalent (CTLT) Reports Q1 Earnings: What Key Metrics Have to Say

Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.

Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential

Syringe maker Catalent (CTLT) said soaring demand for injectable weight-loss drugs could lead to big revenue gains, and shares surged over 11%.

Syringe Maker Catalent Anticipates Boost From Demand for Injectable Weight-Loss Drugs

Catalent, Inc. (NYSE:CTLT ) Q1 2024 Earnings Call Transcript November 15, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President of Investor Relations John Greisch - Executive Chair of Board Alessandro Maselli - President and Chief Executive Officer Matti Masanovich - Senior Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Luke Sergott - Barclays Dave Windley - Jefferies Justin Bowers - Deutsche Bank Jack Meehan - Nephron Research John Sourbeer - UBS Max Smock - William Blair Derik De Bruin - Bank of America Paul Knight - KeyBanc Eric Coldwell - Baird Rachel Vatnsdal - JP Morgan Thomas Kelliher - RBC Capital Markets Operator Hello all, and welcome to Catalent's First Quarter Fiscal Year 2024 Earnings Call. My name is Lydia and I'll be your operator today.

Catalent, Inc. (CTLT) Q1 2024 Earnings Call Transcript

Catalent shares added more than 11% after the contract drugmaker's preliminary first quarter earnings topped expectations and it reaffirmed its full-year fiscal 2024 guidance. For the quarter ended in September, Catalent reported a 4% year-over-year drop in revenue from $1.02 billion to $982 million, above Wall Street estimates of $933.2 million.

Catalent doubles down on full year outlook as preliminary 1Q earnings beat estimates

Contract drug manufacturer Catalent on Wednesday beat Wall Street estimates for quarterly revenue as production showed signs of improvement on the back of a change in management.

Catalent beats quarterly revenue estimates

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced preliminary financial results for the first quarter of fiscal 2024, which ended September 30, 2023. “As Catalent continues to execute our strategy to enhance value for our stakeholders, the strength of our internal pipeline and our solid first quarter financial performance give us the confidence to reiterate our guidance for.

Catalent, Inc. Reports Preliminary First Quarter Fiscal 2024 Results and Reaffirms Full-Year Fiscal 2024 Guidance

Catalent will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company's consumer health and biomodalities unit, the company said late Monday.

Catalent delays quarterly filing with SEC on $700 mln impairment charge

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Catalent (CTLT) Q1 Earnings Expected to Decline

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release preliminary financial results for the first quarter of fiscal year 2024 ended September 30, 2023, before the market open on Wednesday, November 15, 2023. Catalent's management will host a webcast to discuss the preliminary results at 8:15 a.m. ET on the same day. Catalent invites all interested parties t.

Catalent, Inc. Announces First Quarter Fiscal Year 2024 Earnings Conference Webcast

Dollar General

The S&P 500 just dropped for the third straight month — clobbering most S&P 500 investors. But there's still plenty of ways to profit.

10 Stocks Turn $10,000 Into $158,688 In 10 Months

Avantor Inc.

Danaher

DexCom

Inspire Medical Systems Inc

Coca-Cola

Eli Lilly

Novo Nordisk

PepsiCo

Insulet

Repligen

Thermo Fisher Scientific

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported a 3% increase in revenue for the quarter-ended June 2023, but Biologics revenue was down 37% year-over-year. Catalent's margins have weakened, with gross profit down 49% year-over-year and EBITDA down over 90% year-over-year.

Catalent Remains Overvalued

Valero Energy

Stocks tanked right on cue in September. But nimble S&P 500 investors are still finding ways to make big money.

9 Stocks Turn $10,000 Into $141,941 In 9 Months

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an exclusive development and license agreement with Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities. Under the terms of the agreement, Melt Pharmaceuticals will utilize Catalent's proprietary Zydis® orally disintegrating tablet (ODT) f.

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent's Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza's Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at M.

Catalent Appoints David McErlane as Biologics Segment Leader

Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company.

Activist Elliott makes inroads at Catalent to build value. Here's what could happen next

Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in compliance with listing rules due to a delay in filing its annual form 10-K with the Securities and Exchange Commission. The company has six months from Sept.

Catalent gets NYSE notice that it's not in compliance with listing rules over late 10-K filing

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, on September 14, 2023, it received a notice (the “NYSE Notice”) from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manu.

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Advance Auto Parts

Bio-Rad Laboratories

Estee Lauder

Enphase Energy

Etsy

KeyCorp

MarketAxess Holdings

Mosaic

Moderna

Newell Brands

Paramount Global

ResMed

SolarEdge Technologies

Sealed Air

Walgreens

Window dressing is a deceitful practice where mutual funds and other large institutions buy high-flying stocks and sell off the losing ones just before the end of a quarter, when many funds must report their holdings.

These Stocks Could Face Selling Pressure Soon

News for Catalent Stock (CTLT)